Albany, N.Y., USA - AMRI announces that it has appointed Christopher Conway as senior vice president of discovery and development and global commercial sales.
Article continues below
Mr. Conway will head up the Company's global Discovery and Development Services (DDS) business, and will retain responsibility for corporate sales and marketing.
Mr. Conway joined AMRI in 2008 as a Business Development Manager with AMRI's U.S. discovery team.
He was promoted to Senior Director of the North America discovery market in 2010 and then to Vice President of Business Development in 2012 leading an international team of business development managers in North America and Europe.
He was promoted to Senior Vice President, Global Sales and Marketing in 2014.
Before joining AMRI, Mr. Conway held sales and leadership positions of increasing responsibility at Johnson and Johnson and completed J&J's Commercial Leadership Development Program.
He succeeds Michael A. Luther, Ph.D., MBA, who is leaving AMRI to pursue other opportunities.
In a related announcement, AMRI welcomes Rory Curtis who joins AMRI as Vice President of Discovery Biology and Pharmacology.
Dr. Curtis, who joins AMRI from Cubist Pharmaceuticals, will also serve as the site head with responsibility for scientific operations at AMRI's Buffalo, N.Y. location.
Dr. Curtis was most recently Senior Director of Human Diseases in Discovery at Cubist Pharmaceuticals, where he developed Cubist's antibacterial drug discovery into new disease areas such as pain, inflammation and gastro-intestinal disease.
Prior to that, he was Senior Director of Research at Elixir Pharmaceuticals, where he built a drug discovery platform developing small molecules to target diseases of aging.
Prior to that, Dr. Curtis held positions of increasing responsibility at Millennium Pharmaceuticals, focused on the discovery of novel genes as drug targets and developing high-throughput screens.
Dr. Curtis began his career at Regeneron Pharmaceuticals developing neurotrophic factors for the treatment of neurodegenerative disease.
Dr. Curtis earned his Ph.D. in Biochemistry from Imperial College of Science, Technology and Medicine (University of London, UK). ■